For instance, the research by Zou et al. (2022) provides a detailed analysis of how m6A modification regulates FGFR4 expression and its impact on ferroptosis in HER2‐positive breast cancer, offering new insights into potential therapeutic approaches for this challenging subtype of breast cancer. Here, ERBB2 is linked to breast carcinoma.